Maynard Um
-
-
-
-
-
-
-
Apellis Pharmaceuticals (APLS) Reiterated at Overweight by Cantor Fitzgerald
-
-
-
-
-
-
-
Apellis Pharmaceuticals (APLS) PT Lowered to $19 at Mizuho
-
-
-
-
-
-
-
Goldman Sachs Downgrades Apellis Pharmaceuticals (APLS) to Sell
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Apellis Pharmaceuticals (APLS)
-
-
-
-
-
-
-
Apellis Pharmaceuticals (APLS) PT Raised to $29 at Wells Fargo
-
-
-
-
-
-
-
Apellis Pharmaceuticals (APLS) Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
-
-
-
-
-
-
-
Mizuho Reiterates Neutral Rating on Apellis Pharmaceuticals (APLS)
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

